Your browser doesn't support javascript.
loading
Tricuspid Valve Academic Research Consortium Definitions for Tricuspid Regurgitation and Trial Endpoints.
Hahn, Rebecca T; Lawlor, Matthew K; Davidson, Charles J; Badhwar, Vinay; Sannino, Anna; Spitzer, Ernest; Lurz, Philipp; Lindman, Brian R; Topilsky, Yan; Baron, Suzanne J; Chadderdon, Scott; Khalique, Omar K; Tang, Gilbert H L; Taramasso, Maurizio; Grayburn, Paul A; Badano, Luigi; Leipsic, Jonathon; Lindenfeld, JoAnn; Windecker, Stephan; Vemulapalli, Sreekanth; Redfors, Bjorn; Alu, Maria C; Cohen, David J; Rodés-Cabau, Josep; Ailawadi, Gorav; Mack, Michael; Ben-Yehuda, Ori; Leon, Martin B; Hausleiter, Jörg.
Afiliação
  • Hahn RT; Department of Cardiology, Columbia University Irving Medical Center, New York, New York, USA.
  • Lawlor MK; Cardiovascular Research Foundation, New York, New York,USA.
  • Davidson CJ; Department of Cardiology, Columbia University Irving Medical Center, New York, New York, USA.
  • Badhwar V; Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Sannino A; Department of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, West Virginia, USA.
  • Spitzer E; Baylor Research Institute, The Heart Hospital Baylor Plano, Plano, Texas, USA.
  • Lurz P; Department of Advanced Biomedical Sciences, Division of Cardiology, Federico II University, Naples, Italy.
  • Lindman BR; Cardialysis, Rotterdam, the Netherlands.
  • Topilsky Y; Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Baron SJ; Heart Center Leipzig at University of Leipzig, Leipzig, Germany.
  • Chadderdon S; Structural Heart and Valve Center, Cardiovascular Division, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Khalique OK; Department of Cardiology, Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Tang GHL; Division of Cardiology, Lahey Hospital and Medical Center, Burlington, Massachusetts, USA.
  • Taramasso M; Baim Institute of Clinical Research, Boston, Massachusetts, USA.
  • Grayburn PA; Knight Cardiovascular Institute, Oregon Health and Science University, Portland, Oregon, USA.
  • Badano L; Division of Cardiology, Saint Francis Hospital and Catholic Health, Roslyn, New York, USA.
  • Leipsic J; Department of Cardiovascular Surgery, Mount Sinai Health System, New York, New York, USA.
  • Lindenfeld J; Herzzentrum Hirslanden Zürich, Zürich, Switzerland.
  • Windecker S; University of Zürich, Zürich, Switzerland.
  • Vemulapalli S; Baylor Scott and White Heart and Vascular Hospital at Plano, Plano, Texas, USA.
  • Redfors B; Department of Medicine and Surgery, University of Milano Bicocca, Milan, Italy.
  • Alu MC; Department of Cardiology, Istituto Auxologico Italiano, IRCCS, Milan, Italy.
  • Cohen DJ; Department of Radiology and Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Rodés-Cabau J; Vanderbilt Heart and Vascular Institute, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Ailawadi G; Department of Cardiology, University Cardiovascular Center, Bern University Hospital, Inselspital, Bern, Switzerland.
  • Mack M; Duke Clinical Research Institute, Durham, North Carolina, USA.
  • Ben-Yehuda O; Duke University School of Medicine, Durham, North Carolina, USA.
  • Leon MB; Cardiovascular Research Foundation, New York, New York,USA.
  • Hausleiter J; Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Eur Heart J ; 44(43): 4508-4532, 2023 11 14.
Article em En | MEDLINE | ID: mdl-37793121
ABSTRACT
Interest in the pathophysiology, etiology, management, and outcomes of patients with tricuspid regurgitation (TR) has grown in the wake of multiple natural history studies showing progressively worse outcomes associated with increasing TR severity, even after adjusting for multiple comorbidities. Historically, isolated tricuspid valve surgery has been associated with high in-hospital mortality rates, leading to the development of transcatheter treatment options. The aim of this first Tricuspid Valve Academic Research Consortium document is to standardize definitions of disease etiology and severity, as well as endpoints for trials that aim to address the gaps in our knowledge related to identification and management of patients with TR. Standardizing endpoints for trials should provide consistency and enable meaningful comparisons between clinical trials. A second Tricuspid Valve Academic Research Consortium document will focus on further defining trial endpoints and will discuss trial design options.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Insuficiência da Valva Tricúspide / Implante de Prótese de Valva Cardíaca Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Eur Heart J Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Insuficiência da Valva Tricúspide / Implante de Prótese de Valva Cardíaca Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Eur Heart J Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos